Fda Approves Amgen's Xgeva™ (Denosumab) For The Prevention Of Skeletal-Related Events In Patients With Bone Metastases ...
Amgen Inc. (NASDAQ: AMGN) announced that the U.S. Food and Drug Administration (FDA) has approved XGEVA™ (denosumab), the first and only RANK Ligand inhibitor for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors. XGEVA was approved following a 6 month priority review by the FDA, a designation reserved for drugs that offer major advances in ...
Read more on Medical News Today
Orignal From: Fda Approves Amgen's Xgeva™ (Denosumab) For The Prevention Of Skeletal-Related Events In Patients With Bone Metastases ...
Post a Comment